LONDON (ShareCast) - (Sharecast News) - Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial.
Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow.

The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to be completed by the end of the first quarter of 2021.

Chairman Cathal Friel said: "This is another exciting new contract win with a new customer for Open Orphan's subsidiary hVIVO as we convert the substantial pipeline that is building up within the company.

"As a group, we are focused on winning and delivering high-quality, profitable contracts and this is another example of our delivery against that strategy."

As of 1020 BST, Open Orphan shares were up 4.84% at 14.08p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE